Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Go back to Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split| Curis, Inc. (NASDAQ: CRIS) | Delayed: 1.35 -0.02 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.37 | 52 Week High | $3.70 | |||
| Open | $1.37 | 52 Week Low | $1.25 | |||
| Day High | $1.39 | P/E | N/A | |||
| Day Low | $1.30 | EPS | $-0.15 | |||
| Volume | 96,907 | |||||
